Anetumumab is a human monoclonal antibody which it's used to treat head and neck cancer.
Read article at Wikipedia
Anetumumab
We can tell you that Anetumumab is a…
If you know more about Anetumumab, you can add more facts here »
Similar topics in Freebase
-
Adalimumab
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody,... -
Abagovomab
Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack... -
Apolizumab
Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers. -
Adecatumumab
Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326). Adecatumumab has been used in clinical studies of treatment in prostate and breast cancers. -
Abatacept
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and... -
Anti-Trail mAB
-
Atlizumab
Atlizumab is a humanized monoclonal antibody which is used as an immunosuppressive drug. -
Aselizumab
Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L. -
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody that targets CD23. It acts as an immunomodulator and, as of October 2009, it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia. -
Afelimomab
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.
